Triazoles are the mainstay treatment for aspergillosis, though resistance to these 26 antifungal agents may be associated with treatment failure. Refractory infections often 27 necessitates the switch to other antifungal agents, including amphotericin B (AMB), 28
Introduction 49
Aspergillus fumigatus is the most common species associated with invasive aspergillosis 50 (IA), an opportunistic infection associated with high morbidity and mortality. Triazoles 51 such as voriconazole (VRZ) and posaconazole are the mainstay of oral therapy and 52 prophylaxis of aspergillosis. These compounds are fungistatic, inhibiting the enzyme 53 complexes involved in the production of ergosterol, a key molecule involved in cell 54 membrane integrity. However, the emergence of acquired azole resistance mechanisms 55 among A. fumigatus isolates, such as alterations in the Cyp51a locus, is increasingly 56 common and associated with treatment failure, leading to mortality rates of >88% in 57
Europe [1] . Amphotericin B (AMB) is an alternative therapeutic option for IA, such as in 58 patients who cannot tolerate VRZ or those who fail to respond to azoles. 59 60 AMB is a fungicidal compound that actively binds to ergosterol and directly disrupts 61 membrane integrity. Polyene resistance has not been a major clinical problem to date. 62 However, there have been an increasing number of reports of clinically significant AMB 63 resistance in fungal pathogens. A meta-analysis by Sterling and Merz (1998) reported 64 that 59% of AMB resistance was acquired during treatment, and 86% of these cases did 65 not clear infection [2] . The mechanism of AMB resistance in A. fumigatus is not yet fully 66 understood. Recent studies have reported that A. fumigatus has the capacity to form 67 biofilms, and these display adaptive antifungal resistance mechanisms [3] [4] [5] . It has been 68 shown that these mechanisms confer altered resistance phenotypes depending on the 69 phase of biofilm growth. A mutation in the ergosterol biosynthesis pathway has been 70 reported to cause azole resistance and consequently triggers cross-resistance to AMB in 71
Materials and methods 84

Strains and media 85
A. fumigatus Af293, and three clinical strains isolated from the Royal Hospital for Sick 86
Children (Yorkhill Division, Glasgow) were used throughout this study. For conidial 87 preparation isolates were propagated on Sabouraud dextrose agar for 72h and conidia 88 harvested, quantified and standardised to 1 × 10 5 conidia/mL in MOPS buffered RPMI 89 for all subsequent studies, as described elsewhere [3] . Previous studies show that both VRZ and AMB exhibit their greatest activity against 184 newly germinated conidia compared to multicellular hyphae [9] . However, AMB is 185 generally more effective than VRZ against the fully formed hyphal populations, which 186 may be due to the fact that AMB does not require actively growing cells to elicit its action. 187 This is clear from time kill studies showing that AMB displayed rapid and highly 188 significant antifungal activity compared to VRZ after only 1 h (Figure 1) . Nevertheless, 189
increased resistance to all agents tested was observed in older hyphal populations 190 which may be due in part to the presence of extrapolymeric material [11] . 191
192
Due to the resistance of older hyphal populations, we focussed on the early germinated 193 hyphal phase of growth to determine how rapidly each drug elicits its action. The data 194 indicated that, while AMB was significantly more active at 1 h, both drugs were highly 195 effective with no significant differences between them at 4, 12 and 24 h. When both 196 drugs were tested in combination, a significant reduction in activity compared to either 197 drug alone was seen. This is in contrast to studies performed with planktonic cells, 198 Candida by AMB has shown to be significantly reduced after pre-exposure to either 211 fluconazole or itraconazole for 16h [7] . When it comes to the mechanism of resistance 212 SEM images suggest that VRZ treatment increases ECM production ( Figure 2B 
